Choose Genopole® and succeed in biotech

Genopole® Entreprises

The «Genopole® Entreprises» service offers high added value, operational business support which takes into account all the specific aspects of doing business in the life sciences. 2 in terms of market knowledge, competitive positioning, achievement of proof of concept, IP 

strategy, corporate funding, product & process industrialization and business development.  2 internationally, by guiding corporate projects along the right lines (advice on European funding, etc.). 2 facilitating market validation via fundraising assistance and industrial alliance building.

2 A team of experienced professionals. Five project managers dedicated to the incubation, incorporation and development of start-ups.

2 An expert committee (formed by acknowledged specialists from academia and business) vali-dates the scientific aspects and the technical & economic feasibility of each project.

2 Access to the Genopole® Day One pre-seed fund whose investment criteria enable it to inject cash very rapidly in a project’s early development stages, thus enabling rapid progression to incorporation and a solid equity position.

2 A comprehensive, diversified real estate offering with stylish architecture in a land-scaped environment.

2 Shared-access technological infrastructure is specifically designed for life science compa-nies and is unique in France, thanks to pooled skills and resources.

2 Genopole® accreditation, which formal-izes the commitment of current and future biopark companies to the principles guiding Genopole®’s action.

 From the idea to the market: incubation, business  support and development services for biotech start-ups

 Ensure your success by locating to Genopole® in Evry, France

k Top-class resourcesGenopole®’s Evry bioscience and biobusi-ness park provides you with the skills, tools and stimulating environment which will fos-ter your success.

Genopole®: biotech success, here and now

  Custom real estate solutionsWith over 83,000 square meters of biotech-dedi-cated real estate, Genopole is the only biopark in France to offer specific, modular solutions (from just a few dozen square meters up to several thou-sand): 2 free use of office space for project champions.  2 a business incubator in partnership with the 

Essonne Chamber of Commerce and Industry (CCIE),  featuring biotech-dedicated, ready-equipped office and lab space. 2   f lexible,   l i fe-science-fr iendly business accommodation solutions, ranging from 500 to 2000 square meters in floor space.2 All within a compact, structured biopark. 

k  A benchmark bioparkGenopole® is an economic reality: the Genopole® Entreprises team will help you relocate to the Evry biopark and will provide support to help you grow your business, develop new projects, create jobs and add value. Our mission is to make your biotech company a success.

  A unique range of facilitiesThe Genopole® biopark can provide you with a range of easy-access and cost-effective shared technological resources. Our scientific and industrial infrastructure covers a broad spectrum of needs:2 technology platforms (a 1500-sqm rodent house, imaging/cytom-etry, mass spec, etc.).2 two national facilities (DNA microarray and plant DNA microarray production platforms). 2 technical facilities (company incubator, NMR workstations, atomic force microscopy, electron microscopy, etc.).2  cutting-edge equipment and shared services (campus digital library, convention center) and highly skilled technical staff.

The Genopole® companies

*  Genopole 1er jour pre-seed fund portfolio companies.

Biopharmaceuticals   

Therapeuticarea

Company Targetdiscovery Drug Formulation Diagnostics Autoimmune Oncology Infectious Metabolic Ophthalmology Otherornot

&validation discovery disease disease disorders specified AbagAcriterAisa Therapeutics Arterial Remodeling TechnologiesAssistmovAtragene Bio Informatics *Genopole Biomanufacturing CenterBiofordsBiomethodesBioQuantaBio SupportBiosolutionBioSystems International Bracer BiotechCellVaxCellVirCelogosCentaure MetrixDNA TherapeuticsDrugabilisEpixis *Flowgene *Gene Signal GenethonGenewave *GenOdyssee *Genomining *Genoplante Valor SASGenOptics *GenoSafeImageneIntegraGenI-Stem LTK FarmaMAT BiopharmaMilleGenNanobiogeneNanoVecNautilus Biotech *Nokad *NovacytNovagali Pharma *ObeTherapy Biotechnology *PartnerChipPharmabridgePhysikronSanofi-Aventis Evry Genetics CenterSebiaSerial Genetics *SinoviaSphergenStatlifeSigma-Aldrich / ProligoTcLandTech Innovation *TexcellTheraclion *Vaxon Biotech *ViroxisVisiorelWatchfrogWittycellXentech

Thedrugdiscoveryvaluechain

3%3%2%

Breakdown by corporate activity in 2006

biomedtech/healthcare drug targets: 5% drug discovery: 35% diagnostics: 11% drug delivery: 9%

instrumentation

other (services)

bioinformatics

chemistry

the environment

the agro-industry60%

17%

9%

6% 

Agrifood Theenvironment Chemistry Bioinformatics Medicalequipment andcomputer andinstrumentation science

Biopharmaceuticals   

Therapeuticarea

Company Targetdiscovery Drug Formulation Diagnostics Autoimmune Oncology Infectious Metabolic Ophthalmology Otherornot

&validation discovery disease disease disorders specified AbagAcriterAisa Therapeutics Arterial Remodeling TechnologiesAssistmovAtragene Bio Informatics *Genopole Biomanufacturing CenterBiofordsBiomethodesBioQuantaBio SupportBiosolutionBioSystems International Bracer BiotechCellVaxCellVirCelogosCentaure MetrixDNA TherapeuticsDrugabilisEpixis *Flowgene *Gene Signal GenethonGenewave *GenOdyssee *Genomining *Genoplante Valor SASGenOptics *GenoSafeImageneIntegraGenI-Stem LTK FarmaMAT BiopharmaMilleGenNanobiogeneNanoVecNautilus Biotech *Nokad *NovacytNovagali Pharma *ObeTherapy Biotechnology *PartnerChipPharmabridgePhysikronSanofi-Aventis Evry Genetics CenterSebiaSerial Genetics *SinoviaSphergenStatlifeSigma-Aldrich / ProligoTcLandTech Innovation *TexcellTheraclion *Vaxon Biotech *ViroxisVisiorelWatchfrogWittycellXentech

Production

 Full throtle toward biomanufacturing!In order to make Genopole one of the world’s leading locations for biomanufacturing, 6 new entities will be created:2 the Genopole Biomanufacturing Center, for GMP production of recombinant proteins and monoclonal antibodies; due to open in 2008, this will be the largest facility in France and one of the top ten in Europe. 2 a GMP production unit for Généthon’s viral vectors.2 a biocatalysis and enzyme production center.

2 a cell engineering laboratory. 2 a pharmaceutical development unit for formula-tion and aseptic dispensing.2 a second GMP biomanufacturing unit using complementary non-animal-cell technologies (yeast, bacteria, etc.).Plusthe launch of a plant biomanufacturing project. 

2 The 1000-bed South Ile-de-France Medical Center will host a clinical and translational research center with between 3000 and 5000 sqm of floor space. Groups of academic and private-sector researchers will work along-side clinicians, medical laboratories and companies, with a primary focus on genomics, genetics and biotech. This center is the fruit of a consortium formed by the AFM (the French Muscular Dystrophy Association), Généthon, Genopole®, INSERM (the French National Institute for Health and Medical Research), the University of Evry Val-d’Essonne, the University of Paris-XI and the CEA (the French Atomic Energy Commission).

  The Clinical and Translational  Research Center

k  Sharing skills and servicesJ In late 2005, several Evry campus companies founded an employers’ group in order to share high added value human resources and skills. BioSupport now employs an experienced Administrative & Financial Director and an Administrative Assistant and twelve companies benefit from their services. J In 2008, Genopole® Services will provide companies with new, operational solutions in shared human resources (recruitment assistance, employment contracts, etc.), purchasing (consumables, maintenance services, etc.) and technical maintenance (IT, lab material, etc.).J Also under study: the constitution of joint Staff Committees for companies with fewer than 50 employees but which would like to provide their staff with additional benefits.

  In 20102 a Biotherapy Institute  in collaboration with the AFM and the INSERM, in order to draw together the campus’s research skills in the fields of stem cells and gene & cell therapy. 2 an on-campus small animal in vivo imaging platform, interfaced with the existing CERFE  animal facility and which would primarily service biotech companies (in collaboration with the CEA and in coherence with the existing Neurospin and MIRCEN facilities).

Genopole®: the future-ready business location

^ Over 60 companies already on campus or relocating to it.

^ 38 companies incorporated and incubated since 2000.

^ More than e160 million in equity raised by Genopole® member companies, includ-ing €99.3 million by firms in the Genopole Day One fund’s portfolio.

^ 22 products under development, from the regulatory preclinical phase to phase III. 

^ The first marketed treatments are expected for 2008.

^ Over 20 companies generating turn-over, with a total of €58 million in sales.

^ Ten companies have signed collabora-tion agreements or alliances with big pharma.

  More than just promises – we deliver results

More than 1800 people already work in the many academic labs and biotech companies on the Genopole® campus. Within easy walking distance of each other, these entities represent potential customers or partners and can constitute a decisive competitive advantage.

A busy program of national and international seminars, colloquia, meetings, training courses, business breakfasts and business clubs promotes dialogue and development opportunities.

Lastly, Genopole® is a member of the world-class MEDICEN Paris Region cluster, accredited by the French government and which unites all the life science and healthcare stakeholders in the Paris Ile-de-France region. This status means that companies located within the Genopole® campus’s R&D zones receive substantial tax breaks and gain access to additional R&D funding programs.

  A strong network 

Genopole siège – Genopole Campus 1 – Bât. Genavenir 8 5, rue Henri-Desbruères – 91030 Evry Cedex

Tel. : +33 1 60 87 83 00 - Fax: +33 1 60 87 83 01 – www.genopole.fr E-mail us at: firstname.name@genopole.fr

Design/production:                 – Photo credits: A. Da Silva/Graphix Images, X. Renauld, J. Grison/Rapho, Groupe 6 Architectes, DR – Legal deposit: January 2008

Florent Bugat

V Following his Pharm.D. and a Masters in Biological and Medical Sciences, Florent Bugat has obtained his MSc from Toulouse Business School. In 2006, he began his career as

a junior analyst in the Life Science Department at Edmond de Rothschild Investment Partners (Paris), a venture capital fund whose investment strategy is focused on three areas; therapeutics, molecular diagnostics and medical equipment. Florent joined Genopole® in 2007.

Nicolas Lascaud

V Following an industrial Pharm.D., Nicolas completed his training with a Masters in Technology & Innovation Management (jointly accredited by Paris-

Dauphine University and the CEA, the French Atomic Energy Commission). He then carried out several research exploitation and start-up support projects for the CEA’s life science technology transfer department, plus a research/IP exploitation project for the Paris Public Hospital Authority. He progressively specialized in regulatory affairs (and orphan designation in particular). Nicolas joined the Genopole® Entreprises team in 2007.

Véronique Dufey Executive Director of Genopole® Entreprises

V With a degree in Business Law from the University of Paris-II and a Masters in Finance from the Paris Business Administration Institute, Véronique Dufey has experience of two different facets of the world of start-ups. During her 5 years at the “Crédit d’Equipement des PME” public-sector development bank, she was responsible for funding investment programs in small industrial businesses. In 1997, she founded one of the first ever companies to specialize in selective waste recycling on industrial sites. Véronique joined Genopole® Entreprises in June 2001 and took over its management in 2005.

k ContactsFull-time support from a dedicated business start-up and development team.

Eric Lameignere

V Following a PhD at the Institut de Chimie des Substances Naturelles (ICSN) and initial research experience at Rhône-Poulenc Rorer in the UK, Eric Lameignere

completed his training with an MBA from the Euromed Business School (Marseilles, France). Prior to becoming Director of Business Development in a biotech start-up, Eric spent more than twelve years in the pharmaceutical industry, with a particular focus on the development and evaluation of biotech-pharma alliances. Eric joined Genopole® Entreprises in September 2005.

Anne Walrafen

V Anne Walrafen is a graduate of the Ecole Polytechnique in Paris and acquired solid research experience during her PhD in neurobiology. During

this time, she also provided teaching support for undergraduates. Anne then worked as a scientific analyst in the biotech VC department at Société Générale Asset Management, prior to holding a post as a junior business developer manager at ExonHit Therapeutics (also in Paris). Anne joined Genopole® Entreprises in April 2004.

Nathalie Baran

V Following her PhD in endocrinology and molecular biology at Necker Hospital (Paris), Nathalie Baran completed her training with a Masters in

Entrepreneurship & Finance at the European School of Management (Paris). From 2002 on, she pursued a range of activities in innovation support, project management, corporate finance and market launch in both start-ups and institutions such as Oséo (the French state innovation agency). Nathalie joined the Genopole® Entreprises team in November 2006.

Marina Bunelle Investment Manager

V After training as a business translator at the Catholic University of Western France in Angers, Marina Bunelle obtained a Masters in Finance at the Nantes Business Administration Institute and

then worked as a consultant on setting up and running European Union-funded projects. In 1998, she joined the Pays de la Loire Regional Council as an international business development officer for local companies. Marina joined the Genopole® team in November 1999 and, since 2004, has focused exclusively on start-up financing via the Genopole® Day One fund (of which she is a Management Board member).

MINISTÈRE

DE L’ENSEIGNEMENT SUPÉRIEUR

ET DE LA RECHERCHE